 CAMBRIDGE, Mass., May 17, 2021 GLOBE NEWSWIRE -- Sarepta Therapeutics, Inc. NASDAQ:SRPT, the leader in precision genetic medicine for rare diseases, today announced that on Tuesday, May 18, 2021 at 8:30 am Eastern Time, the Company will host a webcast and conference call to present 12-week expression and safety results from Study SRP-9001-103 Study 103, also known as ENDEAVOR. Study 103 is the first clinical trial using Sareptas commercially representative material for SRP-9001 rAAVrh74.MHCK7.micro-dystrophin for the treatment of Duchenne muscular dystrophy. SRP-9001 is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein. 